Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celldex Therapeutics

Division of Celldex Therapeutics Inc.
www.celldextherapeutics.com

Latest From Celldex Therapeutics

FDA Biosimilars Acting Director Yim Is ‘Not A Great Fan’ Of Suffix-Based Naming Policy

Whether one accepts the view that concerns about active pharmacovigilance and the need to distinguish small molecules from biologics support the controversial nomenclature system is ‘a personal thing,’ Sarah Yim says.

Biosimilars Biologics

US FDA Biosimilars Acting Director Yim ‘Not A Great Fan’ Of Suffix-Based Naming Policy

Whether one accepts the view that concerns about active pharmacovigilance and the need to distinguish small molecules from biologics support the controversial nomenclature system is ‘a personal thing,’ Sarah Yim says.


Biosimilars Biologics

Bristol-Myers Boosted By Opdivo Sales, Growth Prospects

Bristol-Myers Squibb Co.'s Opdivo (nivolumab) exceeded expectations in the third quarter and the company's commentary on future indications and combinations for the immunotherapy gave investors hope that sales would continue to blast ahead of Merck & Co.'s competing PD-1 inhibitor Keytruda (pembrolizumab).

Infectious Diseases Cancer

Stockwatch: New Dawns For Life Science Companies

Beneath the surface of a sporadically negative second-quarter earnings season lie two significant changes to the way that life science companies conduct their businesses.

Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Celldex Therapeutics Inc.
  • Senior Management
  • Robert Forbes Burns, PhD, CEO
    Anthony S Marucci, SVP, CFO
    Ronald C Newbold, PhD, SVP, Bus. Dev.
    Tibor Keler, PhD, SVP, R&D & CSO
  • Contact Info
  • Celldex Therapeutics
    Phone: (908) 454-7120
    222 Cameron Dr., Ste. 400
    Ste. 400
    Phillipsburg, NJ 08865
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register